SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.

Andere talen Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Aandelen

688266

CNE100003RP1

slotkoers Shanghai S.E. Andere beurzen 00:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
53,4 ^CNY	+4,38%		+15,78%	+0,87%

19/04	Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI
23/02	Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Rapporteert winstresultaten voor het volledige jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials	12/04
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Zelgen Biopharmaceuticals Grants Yuanda Life Unit Marketing Rights for Recombinant Human Thrombin	08/12
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27-10-23
Zelgen Biopharma’s Phase III Trial of Thyroid Cancer Treatment Yields Positive Results	19-09-23
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index	18-09-23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25-08-23
Zelgen Biopharmaceuticals Gets Nod for China Clinical Trial of Solid Tumor Drug	31-07-23
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma	13-06-23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21-04-23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it has received CNY 1.45529 billion in funding	21-04-23
Zelgen Biopharma Gets Nod for Clinical Trials of Tumor Drug	19-04-23
Zelgen Biopharmaceuticals Wins FDA Nod to Trial Lung Cancer Drug	11-04-23
Zelgen Biopharmaceuticals Certified as High-Tech Enterprise in China	03-03-23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	13-10-22
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18-08-22
Zelgen Biopharma Wins Nod to Launch Clinical Trial of Tumor Treatment	17-08-22
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(SHSE:688266) dropped from Shanghai Stock Exchange Health Care Sector Index	10-06-22
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26-04-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Aandelen

688266

CNE100003RP1

Andere talen

Filters